Press Releases Check out the latest news from Tavanta September 18, 2019 DRGT Announces the U.S. FDA IND Application Approval and First Dosing of a Clinical Trial to Evaluate the Bioavailability and Food Effect of Immediate-Release Formulation of Tadalafil (DRGT-99) July 15, 2019 DRGT Announces Hungarian Regulatory Authority Approval and Subsequent Initiation of a Phase 2 Trial of DRGT-119 in Patients With Chronic Anal Fissure June 10, 2019 DRGT Completes a Pivotal Phase I Trial; Results Confirm 6X Faster Attainment Of Maximum Plasma Levels For Pain Management Compared To Currently Available COX-2 Inhibitor February 05, 2019 DRGT USA Announces Appointment of Dr. Elizabeth Manning Duus, as Executive Director of Clinical Development December 06, 2018 Druggability Technologies USA Announces Appointment of John E. Friend II, M.D. as Chief Medical Officer May 02, 2018 Best in Class Erectile Dysfunction Drug – DRGT announces dose escalation study results of its Super-Tadalafil DRGT-99 October 05, 2017 DRGT announces results of Phase I study expanding clinical utility of the drug Sirolimus utilizing the company’s novel Super-API technology platform December 19, 2016 DRGT’s novel Celecoxib composition – opportunity for low dose, immediate onset of pain relief with the only NSAID COX-2 inhibitor on the market <<123>>
